checkAd

    Arix Bioscience plc  385  0 Kommentare Arix Co-leads $63 Million Series B Investment Round for Imara

    LONDON, March 18, 2019 /PRNewswire/ --

    This Announcement Contains Inside Information Within the Meaning of The EU Market Abuse Regulation No.596/2014

    • Arix co-leads a $63 million Series B investment in new portfolio company Imara
    • Arix commits $15.0 million (£11.3 million)[1] for 10% ownership stake
    • Arix expands breadth of portfolio with investment in sickle cell disease via a later-stage clinical asset in phase 2

    Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces it has invested in new portfolio company Imara, Inc. ("Imara"), a company dedicated to developing novel therapeutics for chronic treatment of Sickle Cell Disease ("SCD") and other hemoglobinopathies.

    As part of the financing, Arix has committed to invest $15.0 million (£11.3 million) for a 10% stake on a fully diluted basis. Arix Investment Director Mark Chin will join Imara's board of directors and Investment Associate John Cassidy will join as an observer.

    Cambridge, MA-based Imara is developing IMR-687, an orally-administered, highly potent and selective phosphodiesterase 9 (PDE9) inhibitor developed to treat the underlying causes of the pathology of sickle cell disease, a condition characterised by sickling of red blood cells and the occlusion or blockage of small blood vessels by the rigid, sickle-shaped red blood cells. The company has a highly experienced leadership team led by Chief Executive Officer Rahul Ballal, formerly the Chief Business Officer at Northern Biologics and Entrepreneur-in-Residence at Versant Ventures. Early clinical data in SCD patients support the potential for IMR-687 to improve health outcomes and possibly ameliorate disease pathology. The mechanism of IMR-687 is differentiated from other therapies in development by its dual action on both red and white blood cells. IMR-687 successfully completed a Phase 1 study in healthy volunteers and is currently being tested in a global Phase 2a study in adult SCD patients, including sites in the UK.

    The financing was co-led by new investors Arix and Orbimed Advisors and also included RA Capital and Rock Springs Capital. Existing investors NEA, Pfizer Ventures, Bay City Capital, Lundbeckfonden Ventures and Alexandria Venture Investments also participated in the fundraise. Proceeds from the financing will be used to progress clinical development in sickle cell disease in adults and children, and broader applications in beta thalassemia and other haematological conditions.

    Seite 1 von 3



    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Arix Bioscience plc Arix Co-leads $63 Million Series B Investment Round for Imara LONDON, March 18, 2019 /PRNewswire/ - This Announcement Contains Inside Information Within the Meaning of The EU Market Abuse Regulation No.596/2014 Arix co-leads a $63 million Series B investment in new portfolio company Imara Arix commits $15.0 …